| Literature DB >> 27342080 |
Javier P Gisbert1, Javier Molina-Infante2, Javier Amador3, Fernando Bermejo4, Luis Bujanda5, Xavier Calvet6, Manuel Castro-Fernández7, Antonio Cuadrado-Lavín8, J Ignasi Elizalde9, Emili Gene10, Fernando Gomollón11, Ángel Lanas11, Carlos Martín de Argila12, Fermín Mearin13, Miguel Montoro14, Ángeles Pérez-Aisa15, Emilio Pérez-Trallero16, Adrián G McNicholl17.
Abstract
Helicobacter pylori approximately infect 50% of Spanish population and causes chronic gastritis, peptic ulcer and gastric cancer. Until now, three consensus meetings on H.pylori infection had been performed in Spain (the last in 2012). The changes in the treatment schemes, and the increasing available evidence, have justified organizing the IVSpanish Consensus Conference (March 2016), focused on the treatment of this infection. Nineteen experts participated, who performed a systematic review of the scientific evidence and developed a series of recommendation that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. As starting point, this consensus increased the minimum acceptable efficacy of recommended treatments that should reach, or preferably surpass, the 90% cure rate when prescribed empirically. Therefore, only quadruple therapies (with or without bismuth), and generally lasting 14 days, are recommended both for first and second line treatments. Non-bismuth quadruple concomitant regimen, including a proton pump inhibitor, clarithromycin, amoxicillin and metronidazole, is recommended as first line. In the present consensus, other first line alternatives and rescue treatments are also reviewed and recommended. Copyright ÂEntities:
Keywords: Bismuth; Bismuto; Clarithromycin; Claritromicina; Helicobacter pylori; Inhibidor de la bomba de protones; Metronidazol; Metronidazole; Omeprazol; Omeprazole; Proton pump inhibitor
Mesh:
Substances:
Year: 2016 PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003
Source DB: PubMed Journal: Gastroenterol Hepatol ISSN: 0210-5705 Impact factor: 2.102